AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01938027 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal total mesorectal excision
Description: Laparoscopy-assisted transanal total mesorectal excision
Study NCT01921166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clomiphene plus gonadotropins
Description: clomiphene plus gonadotropin ovulation induction
Study NCT01921166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide flare
Description: Leuprolide flare ovulation induction
Study NCT03539627 — intervention group
Intervention type: DRUG
Intervention: Azilsartan Medoxomil 40 MG Oral Tablet [Edarbi]
Description: patients are to receive azilsartan medoxomil
Study NCT04314206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-5024
Description: Part 1: one dose~Part 2:~Cohort 1: 10 doses (once a day for 10 days) Cohort 2: 19 doses (once every 12 hours \[q12h\] dosing for 9 days with a single morning dose on Day 10) Cohort 3: 28 doses (once every 8 hours \[q8h\] dosing for 9 days with a single morning dose on Day 10)
Study NCT04314206 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for VNRX-5024
Description: Part 1: one dose~Part 2:~Cohort 1: 10 doses (once a day for 10 days) Cohort 2: 19 doses (once every 12 hours \[q12h\] dosing for 9 days with a single morning dose on Day 10) Cohort 3: 28 doses (once every 8 hours \[q8h\] dosing for 9 days with a single morning dose on Day 10)
Study NCT00990132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home mechanical ventilation
Description: Nocturnal non-invasive ventilation
Study NCT00990132 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Long term oxygen therapy
Description: LTOT established as per national guidelines
Study NCT03878394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise and balance exercises
Description: The first group will be prescribed aerobic exercise and balance exercises as home exercise. Participants in this group will perform 30 min moderate walking exercises and balance exercises. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Exercises will be held once a day for 3 days per week over 6 weeks.Exercise will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
Study NCT02426164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal bupivacaine
Description: Periarticular infiltration of the liposomal bupivacaine with 20cc of normal saline
Study NCT02426164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine HCl, morphine, epinephrine, methylprednisolone
Description: Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone
Study NCT00283517 — intervention group
Intervention type: DRUG
Intervention: antipsychotics
Description: as prescribed
Study NCT03201601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D-chiro-inositol
Description: Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
Study NCT03201601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-chiro-inositol
Description: Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
Study NCT03201601 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Myoinositol
Description: Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
Study NCT03201601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myoinositol
Description: Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
Study NCT02980484 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active
Description: Repetitive transcranial magnetic stimulation (rTMS) will be applied to the left dorsolateral prefrontal cortex (DLPFC) (4000 pulses, 10 Hz, 5-sec trains, 25-sec inter-train interval) followed by the right DLPFC (1000 pulses, 1 Hz frequency, single train). The DLPFC will be identified using individual subject-level resting-state network estimation (Hacker et al, 2013). Each treatment will be completed over the course of 1 hour, and each subject will receive a total of 20 treatments over the course of 20 consecutive weekdays.
Study NCT02980484 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Treatment that looks and feels similar to active rTMS will be administered as a sham treatment.
Study NCT00556140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Everyone in this study will receive aripiprazole and an antidepressant called a selective serotonin reuptake inhibitor (SSRI). There is only one arm for this study.~Aripiprazole is an antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia.~You will receive aripiprazole (Abilify) and one of the following SSRI antidepressant medications that will be determined by the study doctor and you: sertraline (Zoloft), citalapram (Celexa), or escitalopram (Lexapro). The dose of aripiprazole (Abilify) will be 10 milligrams a day, and the starting doses for the SSRI anti-depressants will be: sertraline (Zoloft) 50 milligrams a day, citalopram (Celexa) 20 milligrams a day, and escitalopram (Lexapro) 10 milligrams a day.
Study NCT00270738 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Indirect training of the PFMs via transversus abdominis
Description: Individual visit: twice a month for 4 months. Exercise regimen: diaphragmatic breathing, tonic activation, muscle strengthening, functional expiratory patterns, and impact activities.
Study NCT00270738 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pelvic floor muscle training
Description: Individual visit: twice a month for 4 months. Exercise: intensive pelvic floor muscle training
Study NCT00270738 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: home exercise
Description: PFM exercise at home: at least six high-intensity (near-maximum) contractions 3 times per day at home, with an aim at holding each muscle contraction for 10 seconds, with at least a 10-second rest between contractions.
Study NCT01695707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: see Arm Description
Study NCT01695707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for pioglitazone)
Description: see Arm Description
Study NCT04187066 — intervention group
Intervention type: BEHAVIORAL
Intervention: mindset induction
Description: induction of a health mindset to measure changes in cue-dependent and goal-directed behavior
Study NCT02195479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade
Description: Participants will receive velcade 1.3 mg/m\^2, as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9.
Study NCT02195479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: Participants will receive velcade 1.3 mg/m\^2, as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9.
Study NCT02195479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: Participants will receive melphalan 9 mg/m\^2, orally, once daily on Days 1 to 4 of each cycle up to Cycle 9.
Study NCT02195479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Participants will receive melphalan 9 mg/m\^2, orally, once daily on Days 1 to 4 of each cycle up to Cycle 9.
Study NCT02195479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Participants will receive prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.
Study NCT02195479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will receive prednisone 60 mg/m\^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.
Study NCT02195479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab IV
Description: Participants will receive daratumumab 16 mg/kg as intravenous infusion, once weekly, for 6 weeks in Cycle 1 and then once every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study .
Study NCT02195479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants administered with dexamethasone 20 mg IV or PO is given 1 hour or less prior to daratumumab administration as pre medication and prednisone substitute.
Study NCT02195479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab SC
Description: Daratumumab SC will be administered by SC injection at a fixed dose of 1800 mg once every 4 weeks until documented progression, unacceptable toxicity, or until the end of study. Following amendment 7, participants can switch from daratumumab IV to daratumumab SC.
Study NCT01037452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg
Description: Tablet
Study NCT01037452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Description: Tablet
Study NCT01037452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate/magnesium hydroxide
Description: Tablet
Study NCT01037452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study NCT02094300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zenith® Dissection Endovascular Graft
Description: Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guide the study device(s) into place in the aorta.
Study NCT00017693 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human soluble IL-4 receptor
Description: Subjects were randomized to twelve once weekly nebulizations of 0.75, 1.5, or 3.0 mg dose of recombinant human soluble IL-4 receptor (rsIL-4R)
Study NCT00017693 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Recombinant human soluble IL-4 receptor
Description: Subjects were randomized to twelve once weekly nebulizations of placebo for recombinant human soluble IL-4 receptor (rsIL-4R). Identically prepared (to the recombinant human soluble IL-4 receptor) in the same volume
Study NCT01870778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLX030
Description: 1 mg/mL solution in 6 mL vials
Study NCT01870778 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo solution to serelaxin
Study NCT02961998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Patients from experimental group will take celecoxib, except for sorafenib
Study NCT03050723 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Princess® FILLER
Description: Princess® FILLER injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.
Study NCT04103593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise training
Description: 12-weeks of high-intensity functional circuit exercise that will be broadcasted from the Salem VAMC to older Veterans living with HIV in the Atlanta and Baltimore VAMCs
Study NCT03551158 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Echocardiography
Description: Cardiac imaging for the assessment of the left atrium anatomy and function.
Study NCT04639895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The Virtual Reality group will be involved in the Standard treatment protocol and will perform personalized activities of daily living in a virtual city environment (Reh@City).
Study NCT04639895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paper and Pencil
Description: The paper and Pencil group will be involved in the Standard treatment protocol and will perform personalized cognitive paper-and-pencil tasks, using the Task Generator tool.
Study NCT04639895 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: The standard treatment protocol.
Study NCT01715480 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Broccosprouts® (Brassica Protection Products LLC) homogenate
Description: In the in-vitro part of the study, sulphoraphane will be added into the culture media used to grow and differentiate the erythroid cells from blood samples obtained from three Hb AA volunteers and three Hb SS subjects. The subjects will have a single clinic visit for the blood donation.~In the second part of the study, enrolled subjects will be asked to consume homogenates of broccoli sprouts by mouth daily for three weeks. They will have a maximum of five clinic visits for medical assessments and lab draws during this time. They will then have a final clinic visit after a washout period of six weeks.
Study NCT01143558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lyme Disease Xenodiagnosis
Description: Clean laboratory-bred ticks are the FDA registered IDE. These ticks are placed on patients to search for evidence of Borrelia burgdorferi.
Study NCT03785379 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Trainers will supervise participants during 12-weeks of structured exercise consisting of 150 min/week workouts, divided in three sessions of progressive mixed (aerobic and resistance) exercise. All aerobic exercise will be performed using treadmill and/or cycle ergo-meter.
Study NCT03802747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab will be dosed at 1500 mg fixed dosing every 4 weeks and continued at this interval until progression or dose-limiting toxicity.
Study NCT03802747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab and Tremelimumab
Description: Durvalumab will be dosed at 1500 mg fixed dosing every 4 weeks and continued at this interval until progression or dose-limiting toxicity. Tremelimumab will be dosed at 75 mg every 4 weeks (same day as durvalumab infusion) for a maximum of 4 doses.
Study NCT03802747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Y-90 Selective Internal Radiation Therapy (SIRT)
Description: Yttrium-90 microsphere therapy consists of resin beads loaded with Yttrium, a pure beta emitter with a 64.2 hour half-life. Radioembolization will be performed as standard of care therapy per current NCCN guidelines.
Study NCT03802747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: High-dose hypofractionated conformal external beam radiation therapy that is considered a standard of care. SBRT will also be considered for metastases that are persistent and/or progressive after Y-90 based on MR imaging and pathology from tissue biopsies.
Study NCT04124705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armour® Thyroid
Description: Administered orally once a day. the daily dose could range from 1/4 - 2 grains.
Study NCT03846466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4323 IV/S
Description: IV / Single administration
Study NCT03878394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise and balance exercises with cognitive exercises
Description: The second group will be prescribed cognitive tasks combined with aerobic exercise and balance exercises as home exercises. Participants in this group will have 30 minutes of moderate intensity exercise and cognitive tasks combined with balance exercises. Participants will be asked to count backwards from 20 during the walk and then count back the days of the week back and repeat it for 30 minutes. Balance exercises shall consist of feet static stops for 30 second , one leg stance for 30 second, standing at tandem position for 30 second and uplift exercises at the fingertips for 30 second. Patients will be asked to count backwards from 20 to count the days of the week backwards during balance exercises. Exercises will be held once a day for 3 days per week over six weeks. Participants will be called by the researcher on the days of the exercise and the participant's compliance with the exercise program will be checked.
Study NCT03846466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4323 SC/S
Description: SC / Single administration
Study NCT03846466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KHK4323 IV/M
Description: IV / Multiple administration
Study NCT04124705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levothyroxine
Description: Administered orally once a day; the daily dose could range from 25- 200 µg.
Study NCT00832429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Mapping
Description: Undergo lymph node mapping
Study NCT03846466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV/S
Description: IV / Single administration
Study NCT00535626 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Trident® Tritanium™ Acetabular Shell
Description: Trident® Tritanium™ Acetabular Shell
Study NCT00832429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy
Description: Undergo SLN biopsy
Study NCT00832429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium Tc-99m Sulfur Colloid
Description: Given ID
Study NCT02877303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Given IV
Study NCT02877303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02877303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IT and IV
Study NCT02877303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT02877303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT02877303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Given IV
Study NCT02877303 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02877303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO
Study NCT02877303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IT, IV, and PO
Study NCT02877303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV
Study NCT02877303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given PO
Study NCT02877303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study NCT02877303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT04115098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 200 mg capsules twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
Study NCT03846466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV/M
Description: IV / Multiple administration
Study NCT04115098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen 500 mg tablets twice daily (BID) All 3 medications will be over-encapsulated in identical opaque capsules
Study NCT02961998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Each group will receive sorafenib as basic treatment.
Study NCT02961998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Each group will receive sorafenib as basic treatment.
Study NCT04272892 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital cognitive behavioural therapy for insomnia
Description: 6 weeks of cognitive behavioural therapy for insomnia (Sleepio) delivered online
Study NCT04272892 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep hygiene information
Description: A leaflet detailing advice to improve sleep through changes in sleep hygiene
Study NCT01732757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcaftadine 0.25%
Description: One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
Study NCT01732757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olopatadine 0.2%
Description: One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
Study NCT03846466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC/S
Description: SC / Single administration
Study NCT03010787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single and multiple dose
Study NCT03010787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V565
Description: Open-label single dose